Advertisement
China Pharma's President and CEO, Ms Zhilin Li, said, ''According to theperformance of sales and collection in the third quarter, the companymanagement's strategies on sales promotion and collection seem to have hadeffect. Both our sales growth rate as well as the accounts receivablecollection rate have improved. The company estimates that the operating cashflow in the third quarter could achieve clear improvement and turn to positive.
Advertisement
''In addition, the company has finished every preparation for upgrading tothe AMEX. As soon as the company's share price reaches the basic requirementfor AMEX we will immediately submit our application to transfer to the AMEX.''
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc., develops, manufactures, and markets specialtypharmaceutical products in China that treat a wide range of conditions,including cardiovascular and CNS diseases, infections, digestive diseases andother prevalent diseases. China Pharma Holdings Inc., is registered inDelaware, USA. Hainan Helpson Bio-pharmaceutical Co., Ltd (Helpson), locatedin Haikou City, Hainan Province, China, is a wholly owned subsidiary of ChinaPharma Holdings, Inc. For more information about China Pharma Holdings, Inc.,please visit http://www.chinapharmaholdings.com .
Safe Harbor Statement:
Certain statements in this press release and oral statements made by ChinaPharma on its conference call in relation to this release, constituteforward-looking statements for purposes of the safe harbor provisions underThe Private Securities Litigation Reform Act of 1995. Any statements set forthabove that are not historical facts are forward-looking statements thatinvolve risks and uncertainties that could cause actual results to differmaterially from those in the forward-looking statements, which may include,but are not limited to, such factors as unanticipated changes in productdemand, increased competition, failure to obtain or maintain intellectualproperty protection, downturns in the Chinese economy, uncompetitive levels ofresearch and development, failure to obtain regulatory approvals, and otherinformation detailed from time to time in the Company's filings and futurefilings with the United States Securities and Exchange Commission. Theforward-looking statements made herein speak only as of the date of this pressrelease and the Company undertakes no duty to update any forward-lookingstatement to conform the statement to actual results or changes in thecompany's expectations.For more information, please contact: China Pharma Holdings, Inc. Diana Huang Tel: +86-898-6681-1730 Email: [email protected]
SOURCE China Pharma Holdings, Inc.
